Access to new tailored cancer therapies and reliable patient information - the challenges

Sarah Cannon Research Institute research developments at ASCO 2010

FIRST trial follow up results

Oncotype DX testing to determine adjuvant therapy for breast cancer patients

Molecular chaperones: cancer dependence and druggability

Pertuzumab and trastuzumab combo improves efficacy for HER2-positive breast cancer

Exemestane potential for hormone-receptor positive, early-stage breast cancer in the adjuvant setting

Targeting of breast cancer tumour initiating cells

Issues with reliability in HER2 testing and avastin for metastatic breast cancer

Understanding stem cells to get abreast of breast cancer

Systems biology for the clinician

Cancer micrometastases and circulating tumour cells in breast cancer patients